Abstract
Viral infections are some of the most frequent complications in patients with hematologic malignancies are viral infections. Infections caused by cytomegalovirus, herpes simplex virus, varicella zoster virus, hepatitis B virus and influenza virus are associated with high morbidity and mortality in this vulnerable population. Fortunately, a growing number of antiviral medications and vaccines are allowing for more effective prophylaxis against these pathogens. This article reviews the epidemiology and prophylactic strategies available for these opportunistic viral pathogens.
Keywords: Cytomegalovirus, herpes simplex virus, varicella zoster virus, influenza virus, hepatitis B virus, hematologic malignancy, anti-viral agents, vaccines, prophylaxis, T-cell dysfunction, lymphoid derived leukemia, mye-loid derived leukemia, chronic lymphocytic leukemia, fludarabine, monoclonal antibodies, pneumonitis, alemtuzumab, oral acyclovir
Infectious Disorders - Drug Targets
Title: Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies
Volume: 11 Issue: 1
Author(s): Michael Angarone
Affiliation:
Keywords: Cytomegalovirus, herpes simplex virus, varicella zoster virus, influenza virus, hepatitis B virus, hematologic malignancy, anti-viral agents, vaccines, prophylaxis, T-cell dysfunction, lymphoid derived leukemia, mye-loid derived leukemia, chronic lymphocytic leukemia, fludarabine, monoclonal antibodies, pneumonitis, alemtuzumab, oral acyclovir
Abstract: Viral infections are some of the most frequent complications in patients with hematologic malignancies are viral infections. Infections caused by cytomegalovirus, herpes simplex virus, varicella zoster virus, hepatitis B virus and influenza virus are associated with high morbidity and mortality in this vulnerable population. Fortunately, a growing number of antiviral medications and vaccines are allowing for more effective prophylaxis against these pathogens. This article reviews the epidemiology and prophylactic strategies available for these opportunistic viral pathogens.
Export Options
About this article
Cite this article as:
Angarone Michael, Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies, Infectious Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152611794407773
DOI https://dx.doi.org/10.2174/187152611794407773 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Current Gene Therapy Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art
Current Drug Targets Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)
Current Cancer Drug Targets The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology The Purinome, a Complex Mix of Drug and Toxicity Targets
Current Topics in Medicinal Chemistry Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates
New Emirates Medical Journal Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Editorial [Hot Topic: Targeting Tumor Uniquitin-Proteasome Pathway with New and Old Drugs (Guest Editor: Q. Ping Dou)]
Current Cancer Drug Targets